Novartis Institutes for BioMedical Research
RTH258/brolucizumab
Clinical Trial Protocol CRTH258A2309
A Single -Arm, Open -Label, Multicenter, Phase IIIb Study  to 
Collect Safety  and Electrocardiogram Data on 
Brolucizumab 6 mg Intrav itreal Treatment in Patients w ith 
Neov ascular A ge-Related Macular Degeneration
Document type: Clinical Trial Protocol
EUDRACT number: N/A
Version number: 00 (Original Protocol)
Clinical trial phase: IIIb
Release date: 13-Mar-2019
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Clinical Trial Protocol Template Version 2.0 ( 01-Aug-2018)
Novartis Confidential Page 2
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
Table of contents
Table of contents ................................ ................................ ................................ ................. 2
List of tables ................................ ................................ ................................ ........................ 4
List of figures ................................ ................................ ................................ ...................... 4
List of abbreviations ................................ ................................ ................................ ............ 5
Glossary  of terms ................................ ................................ ................................ ................. 8
Protocol summary ................................ ................................ ................................ .............. 10
1Introduction ................................ ................................ ................................ ....................... 12
1.1 Background ................................ ................................ ................................ ............ 12
1.2 Purpose ................................ ................................ ................................ .................. 13
2Objectives and endpoints ................................ ................................ ................................ ...14
3Study  design ................................ ................................ ................................ ...................... 14
4Rationale ................................ ................................ ................................ ............................ 15
4.1 Rationale for stud y design ................................ ................................ ..................... 15
4.2 Rationale for dose/regimen and duration of treatment ................................ .......... 16
4.3 Rationale for choice of control drugs ................................ ................................ ....16
4.4 Purpose and timing of interim anal yses/design adaptations ................................ ..16
4.5 Risks and benefits ................................ ................................ ................................ ..16
4.5.1 Blood sample volume ................................ ................................ ............ 16
5Population ................................ ................................ ................................ .......................... 17
5.1 Inclusion criteria ................................ ................................ ................................ ....17
5.2 Exclusion criteria ................................ ................................ ................................ ...17
6Treatment ................................ ................................ ................................ ........................... 19
6.1 Study  treatment ................................ ................................ ................................ ......19
6.1.1 Investigational drug ................................ ................................ ............... 19
6.1.2 Additional study  treatments ................................ ................................ ..19
6.1.3 Treatment arms/group ................................ ................................ ........... 19
6.2 Other treatment(s) ................................ ................................ ................................ ..19
6.2.1 Concomitant therap y ................................ ................................ ............. 19
6.2.2 Prohibited medication after Screening.................................................. 20
6.2.3 Restriction for study  subjects ................................ ................................ 20
6.3 Subject numbering, treatment assignment, randomization ................................ ....21
6.3.1 Subject numbering ................................ ................................ ................ 21
6.3.2 Treatment assignment, randomization ................................ .................. 21
6.4 Treatment blinding ................................ ................................ ................................ .22
6.5 Dose escalation and dose modification................................ ................................ ..22
Novartis Confidential Page 3
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
6.6 Additional treatment guidance ................................ ................................ ............... 22
6.6.1 Treatment compliance ................................ ................................ ........... 22
6.6.2 Recommended treatment of adverse events ................................ .......... 22
6.6.3 Emergency  breaking of assigned treatment code ................................ ..22
6.7 Preparation and dispensation ................................ ................................ ................. 23
7Informed consent procedures ................................ ................................ ............................ 23
8 Visit schedule and assessments ................................ ................................ ......................... 24
8.1 Screening ................................ ................................ ................................ ............... 26
8.1.1 Information to be collected on screening failures ................................ .26
8.2 Subject demographics/other baseline chara cteristics ................................ ............. 26
8.3 Efficacy ................................ ................................ ................................ .................. 26
8.4 Safety ................................ ................................ ................................ ..................... 26
8.4.1 Laboratory  evaluations ................................ ................................ .......... 27
8.4.2 Electrocardiogram (ECG) ................................ ................................ .....28
8.4.3 Pregnancy  and assessments of fertility ................................ ................. 28
8.4.4 Ophthalmic examination ................................ ................................ .......28
8.4.5 Appropriateness of safety  measurements ................................ .............. 29
8.5 Additional assessments................................ ................................ .......................... 29
9Study  discontinuation and completion ................................ ................................ .............. 30
9.1 Discontinuation ................................ ................................ ................................ ......30
9.1.1 Discontinuation of study  treatment ................................ ....................... 30
9.1.2 Withdrawal of informed consent ................................ ........................... 30
9.1.3 Lost to follow -up................................................................................... 31
9.1.4 Early study termination by the sponsor ................................ ................. 31
9.2 Study  completion and post -study  treatment ................................ .......................... 31
10Safety  monitoring and reporting ................................ ................................ ........................ 32
10.1 Definition of adverse events and reporting requirements ................................ ......32
10.1.1 Adverse events ................................ ................................ ...................... 32
10.1.2 Serious adverse events ................................ ................................ .......... 33
10.1.3 SAE reporting........................................................................................ 34
10.1.4 Pregnancy  reporting ................................ ................................ .............. 35
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ 35
10.2 Additional Safety  Monitoring ................................ ................................ ................ 36
11Data collection and database management ................................ ................................ ........ 36
11.1 Data collection................................ ................................ ................................ .......36
11.2 Database management and quality  control ................................ ............................ 37
Novartis Confidential Page 4
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
11.3 Site monitoring ................................ ................................ ................................ ......37
12Data analy sis and statistical methods ................................ ................................ ................ 38
12.1 Analy sis sets ................................ ................................ ................................ .......... 38
12.2 Subject demographics and other baseline characteristics................................ ......38
12.3 Treatments ................................ ................................ ................................ ............. 38
12.4 Analy sis of the primary  endpoint(s) ................................ ................................ ......38
12.4.1 Definition of primary  endpoint(s) ................................ ......................... 38
12.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 38
12.4.3 Handling of missing values/censoring/discontinuations ....................... 39
12.4.4 Sensitivity  and Supportive anal yses................................ ...................... 39
12.5 Analy sis of secondary  endpoints ................................ ................................ ........... 39
12.5.1 Safety  endpoints ................................ ................................ .................... 39
12.6 Interim anal yses................................ ................................ ................................ .....39
12.7 Sample size calculation ................................ ................................ .......................... 39
12.7.1 Primary  endpoint(s) ................................ ................................ ............... 39
13 Ethical considerations and adminis trative procedures ................................ ...................... 40
13.1 Regulatory and ethical compliance ................................ ................................ ........ 40
13.2 Responsibilities of the investigator and IRB/ IEC................................ .................. 40
13.3 Publication of study  protocol and results ................................ ............................... 40
13.4 Quality  Control and Quality  Assurance ................................ ................................ .40
14Protocol adherence ................................ ................................ ................................ ............ 41
14.1 Protocol amendments ................................ ................................ ............................. 41
15References ................................ ................................ ................................ ......................... 42
List of tables
Table 2-1 Objectives and endpoints ................................ ................................ ......14
Table 6-1 Investigational drug ................................ ................................ ............... 19
Table 6-2 Prohibited medication ................................ ................................ ........... 20
Table 6-3 Blinding and unblinding plan................................ ................................ 22
Table 8-1 Assessment Schedule ................................ ................................ ............ 24
Table 8-2 Assessments and Specifications................................ ............................ 27
Table 8-3 Laboratory  Assessments ................................ ................................ ........ 27
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ................................ ................................ ......................... 36
List of figures
Figure 3 -1 Study  Design ................................ ................................ ......................... 15
Novartis Confidential Page 5
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
List of abbreviations
ADA anti-drug antibodies
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
AMD age related macular degeneration
anti-VEGF antivascular endothelial growth factor
AST aspartate aminotransferase
AV atrioventricular
BCVA best corrected visual acuity
bpm beats per minute
CFR code of federal regulations
CMO & PS Chief Medical Office and Patient Safety
CNV choroidal neovascularization
CRA clinical research associate
CrCL creatinine clearance
CRF case report form
CRO clinical research organization
e.g. for example
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
EMA European Medicines Agency
EOS end of study
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration
FU follow up
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
h hour
HDL high-densit y lipoprotein
Novartis Confidential Page 6
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
i.e. that is
ICF informed consent form
ICH International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IOP intraocular pressure
IRB Institutional Review Board
IVT intravitreal
kDa kilodalton
LAMA long-acting muscarinic antagonist
LDH low-density  lipoproteins
LABA long-acting beta adrenergic
mAbs monoclonal antibodies
MDRD modification of diet in renal disease stud y
MedDRA medical dictionary  for regulatory  activities 
μL microliter(s)
mg milligram(s)
mL milliliter(s)
mmHg millimeters of mercury
ms millisecond
OU both ey es
PMDA Pharmaceuticals and Medical Devices Agency
q4w every  4 weeks
RBC red blood cell
RPE retinal pigment epithelium
SAE serious adverse event
SAP statistical analy sis plan
scFv single -chain Fv
SE study  eye
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic p yruvic transaminase
SOM study  operations manual
Novartis Confidential Page 7
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
SUSAR suspected unexpected serious adverse reaction
US United States
WBC white blood cell
WHO World Health Organization
WOCBP women of child bearing potential
Novartis Confidential Page 8
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
Glossary  of terms
Assessment A procedure used to generate data required by the study
Biologic Samples A biological specimen including, for example, blood (plasma, serum), 
saliva, tissue, urine, stool, etc. taken from a study subject 
Dosage Dose of the study treatment given to the subject in a time unit (e.g. 100 
mg once a day, 75 mg twice a day)
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study 
data using data collection syste ms, such as Web-based applications, 
interactive voice response sy stems and clinical laboratory interfaces. EDC 
includes the use of Electronic Case Report Forms (eCRFs) which are 
used to capture data transcribed from paper source forms used at the 
point of care
End of the clinical trial The end of the clinical trial is defined as the last visit of the last subject or 
at a later point in time as defined by the protocol
Enrollment Point/time of subject entry into the study at which informed consent must 
be obtained 
Investigational drug/
treatmentThe drug whose properties are being tested in the study
Medication number A unique identifier on the label of medication kits
Other tr eatment Treatment that may be needed/allowed during the conduct of the study 
(i.e. concomitant or rescue therapy)
Patient An individual with the condition of interest for the study
Period The subdivisions of the trial design (e.g. Screening, Treatment, Follow -up) 
which are described in the Protocol. Periods define the study phases and 
will be used in clinical trial database setup and eventually in analysis
Personal data Subject information collected by the Investigator that is transferred to 
Novartis for the purpose of the clinical trial. This data includes subject 
identifier information, study information and biological samples. 
Premature subject 
withdrawalPoint/time when the subject exits from the study prior to the planned 
completion of all study drug administration and/or assessments; at this 
time all study drug administration is discontinued and no further 
assessments are planned
Screen Failure A subject who did n ot meet one or more criteria that were required for 
participation in the study
Study operational 
manual (SOM)SOM provides additional operational guidance/details for study 
procedures and is not part of the Clinical Study Report
Source 
Data/DocumentSource data refers to the initial record, document, or primary  location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource
Start of the clinical trial The start of the clinical trial is defined as the signature of the informed 
consent by the first subject
Study treatment Any single drug or combination of drugs or intervention administered to 
the subject as part of the required study procedures
Study treatment 
discontin uationWhen the subject permanently stops taking any of the study drug(s) prior 
to the defined study treatment completion date (if any) for any reason; 
may or m ay not also be the point/time of study discontinuation 
Subject A trial participant 
Novartis Confidential Page 9
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
Subject n umber A unique number assigned to each subject upon signing the informed 
consent. This number is the definitive, unique identifier for the subject and 
should be used to identify the subject throughout the study for all data 
collected, sample labels, etc.
Withdrawal of study 
consent (W oC)Withdrawal of consent from the study occurs only when a subject does not 
want to participate in the study any longer and does not allow any further 
collection of personal data 
Novartis Confidential Page 10
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
Protocol summary
Protocol number CRTH258A2309
Full Title A Single -Arm, Open -Label, Multicenter, Phase IIIb Study to Collect Safety 
and Electrocardiogram Data on Brolucizum ab 6 m g Intravitreal Treatm ent 
in Patients with Neovascular Age -Related Macular Degeneration
Brief title Study to collect safety and ECG data on Brolucizumab 6 mg Intravitreal 
Treatment in Patients with wet AMD
Sponsor and Clinical 
PhaseNovartis/IIIb
Investigation type Biologic
Study type Interventional
Purpose and rationale The purpose of this study  is to collec t ECG data after a single IVT injection 
of brolucizumab 6mg in patients with neovascular age-related macular 
degeneration (nAMD).
Primary Objective(s) The primary objective of this study is to collect information on ECG after 
intravitreal injection of brolucizumab 6 mg in patients with nAMD. 
Secondary Objectives The secondar y objective is to collect safety data after intravitreal injection 
of brolucizumab 6 mg in patients with nAMD. 
Study design This is a single -arm, open -label, multicenter study  to collect ECG data 
after a single IVT injection of brolucizumab 6mg in patients with nAMD.
Total study duration for each patient is up to 8days.
Population The study population will consist of male and female patients with nAMD. 
Approximately 10-15 patients ≥ 50 years old are expected to be enrolled 
in the US and Pue rto Rico.
Key Inclusion criteriaSigned informed consent MUST be obtained prior to 
participation in the study
Study eye is diagnosed with nAMD and deemed to be eligible 
for intravitreal injection at the discretion of the Investigator
Novartis Confidential Page 11
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
Key Exclusion criteriaTreatment with any ocular intravitreal injection in the study eye 
within the past 7 half -lives prior to Baseline
Diagnosis of ECG abnormalities including:
Clinically significant cardiac arrhythmias, e.g., atrial 
fibrillation, sustained ventricular tachycardia, and clinically 
significant second or third degree AV block without a 
pacemaker
Familial long QT syndrome or known family histor y of 
Torsades de Pointes
Resting heart rate < 5 0 or > 90 bpm at screening
Resting QTcF ≥450 ms (male) o r ≥460 ms (female) at 
screening
Use of concomitant medications that are classified as known 
risk, conditional risk or possible risk to prolong QT/QTc interval 
within 7 half -lives of the drug prior to baseline
History of stroke (including transient ischemic attack, reversible 
ischemic neurological deficit, prolonged reversible ischemic 
neurological deficit) or m yocardial infarction (ST or non- ST 
elevation m yocardial infarction) at any time prior to baseline
Chronic kidney disease as determined as a C rCL at screening 
of <60 ml/min/1.73 m2as determined by the MDRD formula
Uncontrolled high blood pressure defined as a s ystolic value 
≥140 mmHg or diastolic value ≥90 mmHg at screening or 
baseline
Systemic anti -VEGF therapy during the 6 -month period pri or to 
baseline
Electrolyte disturbances determined as out of normal range 
sodium, potassium or calcium serum concentrations at 
screening 
Study treatment RTH258 (brolucizumab )
Efficacy assessments Not applicable
Key safety 
assessmentsElectrocardiogram (ECG), Holter ECG Monitoring, Vital Signs, Ophthalmic 
Exam (including Intraocular Pressure, Biomicroscopy, and 
Ophthalmoscopy ), Phy sical Exam, Screening Labs (Hematology, Clinical 
Chemistry , and Pregnancy)
Data analysisThere are no formal hypotheses in t his study. Incidences between 20 
and 24 h post -injection of clinically relevant treatment emergent changes 
in HR, PR, QRS, and QTc inter val will be listed by patient . The 
frequency and proportion of patient s with QTcF > 450, 480, and 500 ms 
between 20 and 24 h post -injection will be summarized. 
Key words neovascular age-related macular degeneration ,AMD, nAMD, wet AMD, 
RTH258, brolucizumab, ECG, open -label
Novartis Confidential Page 12
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
1 Introduction
1.1 Background
Age-related macular degeneration (AMD) is a chronic eye disease characterized by progressive 
degenerative abnormalities in the central retina (macula) andis the leading cause of severe 
vision loss in people affecting 10%- 13% of individuals over the age of 65 years in 
North America, Europe, and Australia (Kawasaki et al 2010 ; Rein et al 2009 ; Smith et al 2001 ). 
Genetic, environmental and health f actors play an important role i n the pathogenesis of the 
disease (Wong et al 2014 ).
AMD is classified into 2 clinical subty pes: the non-neovascular (atrophic) or dry form and the 
neovascular (exudative) or wet form (Ferris et al 1984 ; Limet al 2012 ; Miller 2013). 
Neovascular AMD is characterized by the growth of abnormal new blood vessels 
(neovascularization) under the retinal pigment epithelium ( RPE) or subretinal space from the 
subjacent choroid, termed choroidal neovascularization (CNV) (Ferris et al 1984 ). These newl y 
formed vessels have an increased likelihood to leak blood and s erum, damaging the retina by 
stimulating inflammation and scar tissue formation. This damage to the retina results in 
progressive, severe, and irreversible vision loss (Shah andDelPriore 2007 ; 
Shah andDelPriore 2009 ). Without treatment, most affected eyes w ill have poor central vision 
(20/200) within 12 months ( Blinder et al 2003 ). 
VEGF has been shown to be elevated in patients with neovascular AMD, and is thought to play 
a key role in the neovascularization process (Spilsbury et al 2000 ). The use of intravitreal (IVT) 
pharmacotherap y targeting VEGF has significantly  improved visual outcom es in patients with 
neovascular AMD (Bloch et al 2012; Campbell et al 2012 ). Anti- VEGF treatments, such as 
ranibizumab (L UCENTIS®) and aflibercept (EYLEA®), inhibit VEGF sign aling pathway s and 
have been shown to halt the growth of neovascular lesions and resolve retinal edema.
Brolucizumab
Brolucizumab (RTH258, formerl y ESBA1008) is a humanized single -chain Fv (scFv) antibod y 
fragment inhibitor of vascular endothelial growth factor with a molecular weight of ~26 kDa. 
Brolucizumab is an inhibitor of VEGF -A and works by binding to the receptor binding site of 
the VEGF -A molecule, thereb y preventing the interaction of VEGF -A with its receptors 
VEGFR1 and VEGFR2 on the surface of endothelial cells.
A low molecular weight (a surrogate for hydrodynamic radius) should increase drug distribution 
into the target site of action, ensuring effective control of anatomical disease activity .This could 
potentially  translate into a more durabl e efficacy  and a reduced treatment burden (number of 
injections) for the patient and health care professional.
Brolucizumab in nA MD
In a single ascending dose Phase I study  (C-10- 083), the median time until patients fulfilled 
protocol defined criteria forreceipt of standard of care treatment was 30 days longer for 
brolucizumab 6 mg (P = 0.036) versus ranibizumab, with the maximum effect on best-corrected 
visual acuity  (BCVA) and central subfield thickness (CSFT) reached at Week 6 for 
brolucizumab versus Week 4 for ranibizumab. In a separate repeat dosing Phase II study 
Novartis Confidential Page 13
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
(C-12-006, OSPREY) comparing brolucizumab 6 mg (n = 44) ever y 8 weeks (q8w), then ever y 
12 weeks (q12w) administration, i.e. administration every q8w and q12w, respectivel y, against 
afliberc ept (q8w administration, n = 45), brolucizumab achieved comparable visual outcome 
during the loading and q8w phase, with a lower number of patients requiring additional rescue 
treatments (5 out of 44 versus 10 out of 45, respectively). Brolucizumab demonst rated a trend 
for greater improvements and more stability  in retinal anatomy  during the 4 cycles of q8w 
dosing (up to Week 40).
In the Phase III Studies RTH258 -C001 (HAWK) and RTH258- C002 (HARRIER), 
brolucizumab demonstrated non-inferiority  to aflibercept in mean change in BCVA from 
baseline to Week 48 in both trials using a non-inferiorit y margin (NIM) of 4 letters. In both 
studies, the treatment effect observed at Week 48 was largel y maintained up to the end of the 
study  (Week 96) in all treatment arms and results for BCVA-related secondary  endpoints at 
Week 96 were overall comparable with those at Week 48. These results were achieved while a 
majority  of patients on brolucizumab 6 mg –56% in HAWK and 51% in HARRI ER –were 
maintained on a q12w (every  12 weeks) dosing interval following the loading phase (baseline 
to Week 8) through Week 48. Patients in the brolucizumab 6 mg treatment group who were on 
q12w at Week 44 revealed probabilities of 81.5 % and 75.4% to remain on q12w up to week 92 
in HAWK and HARR IER, respectively. Brolucizumab 6 mg achieved superior reductions in 
CSFT versus aflibercept in both the head -to-head and mainten ance phases (P = 0.0016 and 
P =0.0023 at Week 16 and Week 48, respectively, in HAWK; P < 0.0001 at both Week 16 and 
Week 48 inHARRI ER). The greater reductions in CSFT observed at Week 48 with 
brolucizumab 6 mg or 3 mg compared to patient s treated with aflibercept 2 mg were maintained 
through Week 96. Brolucizumab safety  was comparable to aflibercept, with the overall 
incidence of adverse events (AEs) balanced across all treatment groups in both studies.
This study , CRTH258A2309, is an ECG collection study on request of the Pharmaceuticals and 
Medical Devices Agency (PMDA) of Japan . Patients from US and Puerto Rico, 50 years old o r 
greater, diagnosed with nAMD will be eligible to participate. All enrolled patients will recei ve 
one (1)intravitreal dose of brolucizumab 6 mgat baseline and will be observed over a study 
period of 8 dayswith a follow up phone call on day  31. 
1.2 Purpose
The purpose of this study is to collect ECG data after a single IVT injection of brolucizumab 
6mg in patients with neovascular age -related macular degeneration (nAMD).
Novartis Confidential Page 14
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
2 Objectives and endpoints
Table 2-1 Objectives and endpoints
Objective(s) Endpoint(s)
Primary Objective(s) Endpoint(s) for primary objective(s) 
To collect information on ECG after 
intravitreal injection of brolucizumab 6 mg 
in patients with nAMDIncidence between 20 and 24 h post- injection 
of clinically relevant treatment emergent 
changes in HR, PR, QRS, and QTc (heart rate 
corrected QT using Fridericia’s formula, 
QTcF) interval (ms)
Secondary Objective(s) Endpoint(s) for secondary objective(s)
To collect safety data after intravitreal 
injection of brolucizumab 6 mg in patients 
with nAMDAny ocular and non- ocular AEs (including 
clinically relevant ECG abnormalities) until the 
end of the study 
3 Study  design
This is a single -arm, open -label, multicenter study  to collect ECG data after a single IVT 
injection of brolucizumab 6 mg in patients with nAMD .
All patient s must provide informed consent before any study-specific procedure is performed. 
At the Screening and Baseline visits, patient sareevaluated for study  eligibility  based on the 
inclusion/exclusion criteria. Patient s who meet all the inclusion and none of the exclusion 
criteria will receive one single intravitreal injection (IVT) of brolucizumab 6 mg during the 
treatment phase of the study .
Triplicate 12-lead ECG recording will be performed at screening to determine eligibility. 
Asecond triplicate 12-lead ECG recording will be collected approximately  2h prior to the 
brolucizumab IVT injection on Day 1. Holter ECG recording will start approximately  1 h prior 
tothe brolucizumab IVT injection and will end approximately  48h after the IVT injection. 
Athird triplicate 12-lead ECG recording will be performed after the conclusion of Holter 
monitoring on Day  3.
The final study  assessment swill be performed at end of study  (EOS) visit on Day 8, i.e. 1 week 
after injection. The EOS visit will be performed via a telephone call. Total study  duration for 
each patient is up to 8days.Additionally , a safet y follow -upphone call will be performed on 
Day 31. Any AEs starting between Day 9and Day 31 arecollec ted in the source documents. 
All SAEs MUST be reported to Novartis safety  according to instructions inSection 10.1.3 SAE 
reporting .
Novartis Confidential Page 15
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
Figure 3-1 Study  Design
4 Rationale
4.1 Rationale for study  design
This multicenter study  is designed to meet the request of the Pharmaceuticals and Medical 
Devi ces Agency  (PMDA) of Japan to provide ECG data on approximately  10-15 patients  at 
the time at which maximum systemic concentration is reached (Tmax) after a single injection 
of brolucizumab 6 mg. The study  design, study  duration, and patient population we re assess ed 
as adequate to meet the agency ’s request. The study is NOT a thorough QT study. The patient 
population is described in Section 5 Population below . 
Furthermore, monoclonal antibodies (mAbs) are not expected to directly inhibit the function of 
ion channels responsible for cardiac repolarization ;therefore ,thorough QT studies are generally 
not required for biotherapeutics (Malik et al 2 010). There are no known preclinical 
cardiovascular safet y signals with b rolucizumab . T he systemic exposure was confirmed to be
very low in human with a median AUCinf ( Area under the concentration- time curve from time 
zero to infinity ) of 5580 ng*h/mL (Investigator’s Brochure) . 
Approximately  1 h before a single injection of brolucizumab, a Holter monitor will provide 
continuous ECG monitoring for 48h; capturing the approximate time at which maximum 
systemic concentra tion is reached (median Tmax was approximately  24 hours post dose). 
Asingle injection is deemed sufficient because it was previously  shown in the RTH258A2201 
study  thatbrolucizumab does not accumulate in the systemic circulation after repeated monthl y 
injections (SHRI KE, RTH258E003) . 
Additionally  long-term ECG data is being collected in an ongoing large Phase III study  of 
brolucizumab 3 mg or 6mg in Japanese patients with diabetic macular edema , CRTH258B2301 .
ECG data for the CRTH258B 2301 study  is collected at baseline and after 52 and 100 weeks of 
first treatment with brolucizumab 3mg, 6mg or aflibercept .

Novartis Confidential Page 16
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
4.2 Rationale for dose/regimen and duration of treatment
The dose and regimen for brolucizumab are based on the following considerations:
Brolucizumab is well tolerated at a dose of 6 mg, based on the previous clinical Phase III 
program in which 1088 patients with nAMD received brolucizumab.
Brolucizumab 6 mg is the maximum feasible dose for a 50 μ LIVT injection based on 
brolucizumab phy sico-chemical properties and is the highest dose that has been tested. 
Brolucizumab 6 mg provides the higher s ystemic exposure after IVT injection as 
compared to the different dose strengths previously  investigated in patients and is foreseen 
as the therapeut ic dose . Thus, the proposed dose and route are appropriate to generate 
ECG data in its target population with brolucizumab.
4.3 Rationale for choice of control drugs
Not applicable. 
4.4 Purpose and timing of interim analy ses/design adaptations
Not applicable.
4.5 Risks and benefits
Intravitreal brolucizumab 6 mg has been administered to 1355 patient swith nAMD for up to 
2years treatment . Further details of the known and potential risks and benefits associated with 
brolucizumab are presented in the RTH258/brolucizumab Investigator’s Brochure.
All intravitreal injection procedures carry  the risk of endophthalmitis, retinal detachment, 
vitreous or retinal hemorrhage, cataract, elevated intraocular pressure, and ocular inflammation. 
These cond itions are apparent on eye exam and most cause symptoms that prompt the patient
to seek immediate evaluation. With respect to endophthalmitis, current best clinical practices 
are used to reduce the risk of endophthalmitis. Despite these practices, endophthalmitis rates 
may approxima te 1 in 1,000 to 1 in 20,000.
As with any antibody , brolucizumab may carry the risk of anaphy laxis or hypersensitivity 
reacti ons and may also elicit the formation of human anti-drug antibodies ( ADA).
The risk to patient s in this trial may be minimized by compliance with the eligibility  criteria 
and study  procedures, as well as close clinical monitoring.
4.5.1 Blood sample volume
Approximately 6 mL of blood is planned to be collected over a period of up to 14days 
(during Screening ), from each patient as part of study screening . Additional samples may be 
required for safet y monitoring.
The timing of blood sample collection isoutlined in the Assessment Schedule ( Table 8-1).
Asummary  blood log is provided in the Site Operations Manual (SOM).
Novartis Confidential Page 17
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
5 Population
The study  population will consist of male and female patients with nAMD. 
Approximately 10-15 patients ≥ 50 years old are expected to be enrolled in the US and 
Puerto Rico.
5.1 Inclusion criteria
Patient s eligible for inclusion in this study  must meet allof the following criteria at screening :
1.Signed informed consent MUST be obtained prior to participation in the study
2.Study  eye is diagnosed with nAMD and deemed to be eligible for intravitreal injection at 
the discretion of the Investigator
5.2 Exclusion criteria
Patient s meeting any of the following criteria are NOT eligible for inclusion in this study.
Noadditional exclusions may be applied by the investigator, in order to ensure that the study 
population will be representative of all eligible patients.
1.Concomitant conditions or ocular disorders in the study  eye at screening which may  cause 
safet y concerns on the judgement of the investigator
2.Any active intraocular or periocular or s ystemic infection or active intraocular 
inflammation at Baseline
3.Treatment with an y ocular intravitreal injection in the study  eye within the past 
7half-lives prior to Baseline
4. Intraocular surgery , prior long -acting therapeutic agent, or ocular drug release device 
implantatio n (approved or investigational) in the study eye any  time during the past 
3months prior to Baseline
5. D iagnosis of ECG abnormalities including:
Clinically  significant cardiac arrhy thmias, e.g., atrial fibrillation, sustained ventricular 
tachycardia, and clinically significant second or third degree AV block without a 
pacemaker
Familial long QT s yndrome or known family history of Torsades de Pointes
Resting heart rate < 50 or > 90 bpm at screening
Resting QTcF ≥ 450 ms (male) or ≥ 460 ms (female) at screening
6.Use of concomitant medications that are classified as known risk, conditional risk or 
possible risk to prolong QT/QTc interval within 7 half-lives prior to B aseline
7.History  of stroke (including transient ischemic attack, reversible ischemic neurologica l 
deficit, prolonged reversible ischemic neurological deficit) or m yocardial infarction (ST or 
non-ST elevation my ocardial infarction) at any  time prior to baseline
8.Chronic kidney  disease as determined as a CrCL at screening of < 60 ml/min/1.73 m2as 
deter mined by  the MDRD formula
9.Uncontrolled high blood pressure defined as a s ystolic value ≥ 140 mmHg or diastolic 
value ≥ 90 mmHg at screening or baseline
10.Systemic anti -VEGF therapy  during the 6 -month period prior to baseline
Novartis Confidential Page 18
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
11.Electrol yte disturbances determi ned as out of normal range sodium, potassium or calcium 
serum concentrations at screening 
12. Concomitant intake of long- acting muscarinic antagonist (LAMA)/ long -acting beta 
adrenergic (LABA) combination therap y
13.History  of hypersensitivity  to any  of the stud y drugs or its excipients or to drugs of similar 
classes as assessed b y the investigator
14.Use of s ystemic orocular (including intravitreal )investigational drugs within 7half-lives 
of baseline, (or within 30 day s/until the expected pharmacody namic effect has returned to 
baseline), whichever is longer or longer if required by  local regulations (observational 
clinical studies solely  involving over -the-counter vitamins, supplements, or diets are not 
exclusionary )
15.Pregnant or nursing (lactating) women
Women of child- bearing potential, defined as all women physiologically  capable of becoming 
pregnant, unless they are using highl y effective methods of contraception while taking study 
treatment .Highly  effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the patient. 
Periodic abstinence (e.g. calendar, ovulation, sy mptothermal, post -ovulation methods) and 
withdrawal are not acceptable methods of contraception
Female sterilizat ion (have had surgical bilateral oophorectom y with or without 
hysterectom y), total hysterectom y, or tubal ligation at least six weeks before taking study 
treatment. In case of oophorectom y alone, onl y when the reproductive status of the woman 
has been conf irmed by follow up hormone level assessment
Male sterilization (at least 6 months prior to screening); For female patients on the study, 
the vasectomized male partner should be the sole partner for that patient
Use of oral (estrogen and progesterone), injected ,or implanted hormonal methods of 
contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or 
other forms of hormonal contraception that have comparable efficacy  (failure rate <1%), for 
example ,hormone vaginal ring or transdermal hormone contraception
In the case of use of oral contraception, women must be stable on the same pill for a minimum 
of 3 months before taking stud y treatment.
Women are considered post-menopausal and not of child bearing potential if they have had 
12months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age 
appropriate history  of vasomotor symptoms) or have had surgic al bilateral oophorectom y 
(with or without hysterectomy ), total hysterectomy ,or tubal ligation atleast six weeks ago. 
Inthe case of oophorectomy  alone, only when the reproductive status of the woman has been 
confirmed by follow up hormone level assessment is she considered not of child- bearing 
potential.
If local regulations deviate from the contrac eption methods listed above to prevent pregnancy , 
local regulations appl y and isdescribed in the informed consent form ( ICF).
Novartis Confidential Page 19
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
6 Treatment
6.1 Stud y treatment
Investigational product (IP) must be stored at 2° to 8°C (35.6° to 46.4°F); DO NOT FREEZE ; 
protect from light.
Details on the requirements for storage and management of study  treatment, and instructions for 
patient numbering, prescribing/dispensing and taking study treatment are outlined in the SOM. 
6.1.1 Investigational drug
Table 6-1 Investigational drug
Investigational Drug
(Name and 
Strength)Pharmaceutical 
Dosage FormRoute of 
AdministrationSupply  Type Sponsor (global or 
local)
Brolucizumab 
(RTH258)
6 mg / 0.05 mLSolution for injection Intravitreal 
InjectionGlass Vials
(in open label 
patient kit)Novartis (global)
Brolucizumab (RTH258) will be provided to the study  sites in a single use, sterile glass vial 
containing sufficient brolucizumab to deliver a 6 mg dose when administering a volume of 0.05 
mL. The content of the study  drug vials must not be split (single use vials). Novartis will provide 
sufficient supplies of brolucizumab for treatment use to al low for completion of the study .
6.1.2 Additional study treatments
No other investigational treatment beyond the single injection of brolucizumab 6mg is included 
in this trial.
6.1.3 Treatment arms /group
All eligible patients enrolled in this trial will receive asingle injection of brolucizumab 6 mg at 
theBaseline visit (Day  1). 
6.2 Other treatment(s)
Treatment after the completion of the study  follow scurrent standard of care or PI discretion . 
Stand ard of care includes non-investigational therapies that are used according to clinical 
practice for the treatment of nAMD in the US or Puerto Rico . Other treatments, including 
off-label use and other clinical interventional trials or managed access programs, are prescribed
or recommended under the responsibility of the investigator.
6.2.1 Concomitant therapy
All medications, procedures and significant non -drug therapies (including physical therap y and  
blood transfusions) administered after the patient was enrolled into the study  must be recorded 
on the appropriate Case Report Forms (CRFs) .
Novartis Confidential Page 20
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt the investigator should contact the Novartis medical monitor before 
randomizing a patient or allowing a new medication to be started. If the patient is alread y 
enrolled, the investigator must contact Novartis to determine if the patient should continue 
participation in the study .
6.2.2 Prohibited medication after Screening
Use of the treatments display ed in the below table are NOT allowed after screening.
Table 6-2 Prohibited medication
Medication Prohibition period Action tak en
QT prolonging agent* From  Screening to Day 8
(EOS) visitStudy 
discontinuation
Anti-VEGF therapy other than assigned 
study medication in both eyes†From  Screening to Day 8 
(EOS) visitStudy 
discontinuation
Systemic Anti -VEGF therapy From  Screening to Day 8 
(EOS ) visitStudy 
discontinuation
Intraocular or periocular injections of 
corticosteroids (except if treatment for AE) 
in both eyesFrom  Screening to Day 8 
(EOS) visitStudy 
discontinuation
*Please refer to https://crediblemeds.org/pdftemp/pdf/CombinedList.pdf
†During the study , if the fellow eye develops visual impairment, it may also be treated with 
standard of care (i.e. treatment of the fellow eye with anti-VEGF medication other than 
brolucizumab )at the discretion of the investigator . If thefellow eyetreatment is required before 
Day 8, then the patient will be earl y discontinued from the trial.
6.2.3 Restriction for study  subjects
For the duration of the study , patient s should be informed and reminded of the restrictions 
outlined in this section. The below advices are suggested guidelines. 
Nonconformity to these advices will NOT result in a protocol deviation.
6.2.3.1 Dietary  restrictions and smoking
1.No alcohol for 24 hours before dosing until after the study evalua tionon Day  3.
2.No cannabis or cannabidiol oil containing products for 24 hours before dosing until after 
the study  evaluation on Day  3.
3.Intake of xanthine (e.g. caffeine) containing food or beverages (i.e., coffee, tea, soda, 
chocolate) must be limited to 4 cups/day  or less 24 hours prior todosing until after the study 
evaluation on Day  3. 
4.Patients should maintain adequate hydration 24 hours prior to dosing until after the study 
evaluation on Day  3. 
Novartis Confidential Page 21
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
6.2.3.2 Other restrictions
During Holter Monitoring:
1.No strenuous ph ysical exercise (e.g. weight training, aerobics, football , etc.) 24 hours 
prior to the treatment visit andfor the entire duration y ou are wearing the Holter Monitor 
(until removal on Day  3). At approximately  22-24 hours after the IVT injection, try  to 
avoid activity  by laying down and resting for 1-2 hours.
2.No bathing or swimming from the time the Holter Monitor electrodes are placed on Day  1 
until it is removed on Day 3. 
3.Try to a void metal detectors, magnets, microwave ovens, electric blankets, electric razors 
and electric toothbrushes while wearing the Holter monitor. 
4.Try to keep cellphones, portable music play ers, and other devices that may exert an 
electric frequency  at least 6 inches from the Holter monitor. 
6.3 Subject numbering, treatment assignment, randomization
6.3.1 Subject numbering
The patient number assigned to a patient at screening remains the unique identifier for the 
patient throughout the study . For information on patient numbering, please see ‘Subject 
numbering’ section in the Site Operations Manual.
6.3.2 Treatment assignment, randomization
Treatment assignment and randomization are not applicable . This is a single -arm, open -label 
study  and all eligible patients will receive t he investigational treatment. 
Novartis Confidential Page 22
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
6.4 Treatment blinding
Treatment blinding is not applicable because this is asingle arm, open -label study . All patients, 
trial si te, and Sponsor staff will know the treatment provided to the patient. 
Table 6-3 Blinding and unblinding plan
Time or Event
Role Randomization 
list generatedTreatment 
allocation & 
dosingSafety event 
(single patient
unblinded)Interim 
Analysis & 
dose 
escalation
Patients N/A UI UI N/A
Site staff N/A UI UI N/A
Global Clinical Supply 
and Randomization 
OfficeN/A UI UI N/A
Statistician/statistical 
programmer/ data 
analystsN/A UI UI N/A
All other sponsor staff 
not identified above 
(trial team, project 
team, management & 
decision boards, 
support functions)N/A UI UI N/A
Key:
UI: Allowed to be unblinded on individual patient level
B: Remains blinded
NA: Not applicable to this study
6.5 Dose escalation and dose modification
Investigational or other study  treatment dose adjustments are not permitted.
6.6 Additional treatment guidance
6.6.1 Treatment compliance
The patient will receive one intravitreal injection of brolucizumab 6 mg performed by a 
qualified ophth almologist. The injection must be recorded on the appropriate eCRF page.
6.6.2 Recommended treatment of adverse events
Medication used to treat adverse events (AEs) must be recorded on the appropriate CRF.
6.6.3 Emergency  breaking of assigned treatment code
Emergency  breaking of the assigned treatment code is not applicable because this is a single 
arm, open label stud y. 
Novartis Confidential Page 23
Clinical Trial Protocol (Version No. 00 ) Protocol No. CRTH258A2309
6.7 Preparation and dispensation
Each study  site will be supplied with study  drug in packaging as described under the 
investigational drugs section. Drug preparation instructions are included in the SOM. 
7 Informed consent procedures
Eligible patient s may  only  be included in the study  after providing (witnessed, where required 
by law or regulation), I RB/IEC -approved informed consent.
If applicable, in cases where the patient 's repr esentative(s) gives consent (if allowed according 
to local requirements), the patient must be informed about the study  to the extent possible given 
his/her understanding. If the patient is capable of doing so, he/she must indicate agreement by 
personall y signing and dating the written informed consent document.
Informed consent must be obtained before conducting any study-specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the patient source documents.
Novartis will provide the investigators a separate document with a proposed informed consent 
form that complies with the ICH/GCP guidelines and regulatory  requirements and is considered 
appropriate for this study . Any chang es to the proposed consent form suggested by the 
investigator must be agreed by  Novartis before submission to the I RB/IEC.
Information about common side effects alread y known about the investigational drug can be 
found in the IB. This information will be included in the patient informed consent and should 
be discussed with the patient during the study  as needed. Any new information regarding the 
safet y profile of the investigational drug that is identified between IB updates will be 
communicated as appropri ate, for example, via an investigator notification or an aggregate 
safet y finding. New information might require an update to the informed consent and then must 
be discussed with the patient.
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirements.
A copy of the approved version of all consent forms must be provided to Novartis after IRB/IEC 
approval.
Refer to the Site Operations Manual for a complete list of I CFs included in this study .
Novartis Confidential Page 24
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
8 Visit schedule and assessments
The Assessment Schedule (Table 8-1) lists all of the assessments and when they are performed. All data obtained from these assessments must 
be supported in the patient’s source documentation.
Patient s should be seen for all visits/ assessments as outlined in the Assessment S chedule ( Table 8-1 ) or as close to the designated day/time as 
possible. Missed or rescheduled visits will not lead to automati c discontinuation. Patient s w ho prematurel y discontinue the study  for any 
reason should be scheduled for a visit as soon as possible, at which time allof the assessments listed for the final visit will be performed. 
Atthis final visit, the adverse event and concomitant medications recorded on the CRF.
Additional details regarding the visit schedule and assessments are located in the SOM. 
Table 8-1 Assessment Schedule
Period Screening Treatment Safety  Follow -up (FU)
Visit Name Screening Day 1 (Baseline )Day 3 (Visit 2) End of Study  (EOS) Safety  Follow -up (FU)
Days -14 to -1 1 3 8 31
Visit Number 1 101 102 199 N/A
Informed consent X
Inclusion / exclusion criteria S S
Demography X
Medical history/current medical conditions X
Prior/concomitant medications X X X X
Physical examination S
Vital signs (Blood Pressure and Pulse Rate) X X2X3
Electrocardiogram (ECG) X X2X
Holter ECG Monitoring X4X5
Hematology X
Clinical chemistry X
Pregnancy and assessments of fertility1X
Novartis Confidential Page 25
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
Period Screening Treatment Safety  Follow -up (FU)
Visit Name Screening Day 1 (Baseline )Day 3 (Visit 2) End of Study  (EOS) Safety  Follow -up (FU)
Days -14 to -1 1 3 8 31
Visit Number 1 101 102 199 N/A
Intraocular Pressure (IOP) OU SE6
Ophthalmic Exam OU SE6
Adverse Events X X X X S
Telephone follow -up X S
Study drug administration X
Study completion information X
X = assessment to be recorded in the clinical database or received electronically from a vendor
OU = Both Eyes
S = assessment to be recorded i n the source documentation only
SE = Study Eye
1Women of childbearing potential only. Urine pregnancy tests will be performed unless local regulations require a serum pregna ncy test.
2Pre-Injection Procedure, performed before Holter monitoring start
3Remove Holter M onitor before Performing Procedure(s)
4Holter monitoring will start approximately 1 h pre dose
5Holter monitoring will end approximately 48 h post dose
6 Assessment performed pre -dose at Baseline and performed post -dose, if required, at Baseline. Post -dose clinically significant abnormal findings should be recorded as 
an AE .
Novartis Confidential Page 26
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
8.1 Screening
Patients will be screened for eligibility  for up to 14 days prior to the Baseline visit. It is 
permissible to re-screen a patient if s/he fails the initial screening; however, each must be 
discussed and agreed with bythe Sponsor on a case-by-case basis. Information on what data 
must be collected for screening failures and further information on re-screening is outlined in 
the Site Operations Manual.
In the case where a safet y laboratory  assessment at screening indicates an electroly te imbalance, 
the invest igator should investigate if the electrol yte disturbance isdue to a chronic underl ying 
disease or if is the sequela of an intercurrent illness (e.g. such as vomiting ordiarrhea due to a 
recent stomach virus or flu) . If the electrolyte imbalance is due to a chronic underlying disease, 
then the patient must be excluded. If the electrol yte imbalance is due to an intercurrent illness 
and the investigator believes the intercurrent illness has adequatel y resolved, then the
investigator may repeat the testonce prior to treatment . If the repeat value remains outside of 
the specified ranges, the patient must be excluded from the study .
8.1.1 Information to be collected on screening failures
Patient s who sign an informed consent form and who are subsequentl y found to be ineligible ,
prior to receiving the injection ,will be considered a screen failure. Information on what data 
must be collected for screening failures is outlined in the Site Operations Manual.
8.2 Subject demographics/other baseline characteristics
Patient demographic and baseline characteristic data are to be collected on all patient s. 
Relevant medical history /current medical condition present before signing the informed consent 
will be recorded. Investigators will have the discretion to record abnormal test findings on the 
appropriate CRF whenever ,in their judgment, the test abnormality  occurred prior to the 
informed consent signature. Details are outlined in the Site Operations Manual. 
8.3 Efficacy
Efficacy  / Pharmacod ynamics are not measured in this study .
8.4 Safet y
Safety  assessments are specified below with the assessment schedule detailing when each 
assessment is to be performed. For details on adverse event (AE )collection and reporting, refer 
to the AE section (Section 10.1.1). The methods, assessment, specification, and recording for 
each assessment will be detailed in the SOM.
Novartis Confidential Page 27
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
Table 8-2 Assessments and Specifications
Assessment Specification
Physical 
examinationA physical examination will be performed at Screening, as a general health 
check according to local clinical practice.
Clinically relevant findings that are present prior to signing informed consent 
must be included in the eCRF capturing Medical History. Significant findings 
identified after providing written informed consent which meet the definition of 
an Adverse Event must be recorded on the appropriate AE eCRF page.
Vital signs Vital signs include BP (systolic and diastolic pressure in mmHg) and pulse rate 
(beats per minute) measurements (see SOM Section 3.2 Vital signs for details) . 
In case there is an elevated blood pressure measurement as specified in the 
exclusion criteria, at the screening and baseline visits, the blood pressure 
measurement may be repeated up to two times within 30 minutes of the first 
measurement (i.e. 3 measurem ents maximumwithin 30 minof the first 
measurement ). If the final repeat measurement is elevated, then the patient is 
not eligible to be enrolled into the study.
If the case there is an out of range heart rateat screening andbaseline, two 
additional repeat readings can be obtained, so that a total of up to three 
consecutive assessments are made, with the subject seated quietly for 
approximately five minutes preceding each repeat assessment. The last 
reading must be within the ranges provided in the eligibility criteria in order for 
the subject to qualify.
On Day 1, vital signs will be measured before the administration of study  
medication. The res ults are rec orded in the eCRF.
Ophthalmic Exam Intraocular Pressure (IOP), Biomi croscopy (slit lamp examination), 
Ophthalmoscopy (funduscopy) will be performed (see protocol Section 8 .4.4
for details) . 
8.4.1 Laboratory  evaluations
Local laboratories will be used for anal ysis of all specimens collected at screening that will be 
used to evaluate systemic status. Any additional samples may be taken for safet y monitoring. 
Collection of these samples will be performed according to the local clinical practice. 
Clinically significant abnormalities must be recorded as either medical history /current medical 
conditions or adverse events as appropriate.
Table 8-3 Laboratory  Assessments
Test Category Test Name
Hematology Hematocrit, hemoglobin, red blood cell (RBC) count, white blood cell (WBC) count 
with differential (absolute and percentage of neutrophils, lymphocytes, monocytes, 
eosinophils, and basophils), and quantitative platelet count
Chemistry Serum electrolytes (sodium, potassium, chloride, phosphorus, calcium, 
magnesium), uric acid, urea nitrogen, creatinine, albumin, glucose, total protein, 
total bilirubin and direct bilirubin, serum glutam ic oxaloacetic transaminase 
(SGOT)/ aspartate aminotransferase (AST), serum glutamic pyruvic transaminase 
(SGPT)/ alanine aminotransferase (ALT), gamm a-glutam yl transferase (GGT), 
alkaline phosphatase (ALP), lactate dehy drogenase (LDH), troponin, high-density 
lipoprotein (HDL), low -density lipoprotein (LDL)
Pregnanc y Test Urine pregnancy testfor women of childbearing potential. If required by local 
regulations, serum testing is accepted
Novartis Confidential Page 28
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
8.4.2 Electrocardiogram (ECG)
Full details of all procedures relating to the ECG collection and reporting are contained in the
core reading center technical manual and in the Site Operations Manual .
Triplic ate 12 lead ECGs (performed at Screening, B aseline pre-injection , and Day 3) and 12 
lead Holter ECG swill be collected with ECG machines supplied by the core ECG reading 
center . All ECGs will be sent to the central ECG reading center. Central ECG reading will be 
used to determine eligibility at Screening .
A monitoring or review process should be in place for clinicall y significant ECG findings 
throughout the study . Only  clinically  significant abnormalities must be reported as adverse 
events.
The Holter ECG recording is performed to capture comprehensive ECG data and should start 
approximately  onehour before IVT injection . The recording will end approximately  48 h after 
injection.
In the event that a clinically  significant ECG abnormality  is identified at the site (e.g. severe 
arrhythmia, conduction abnormality of QTcF > 500 ms), a copy of the assessment is sent to the 
core laboratory  for expedited review if applicable, and the ECG is r epeated to confirm the diagnosis.
If the patient is hemody namically  compromised, the investigator or a medically qualified person must 
initiate appropriate safety  procedures without delay  (for example cardioversion ).
Clinically  significant abnormalities must be recorded on the eCRF as either medical 
history /current medical conditions or adverse events as appropriate.
8.4.3 Pregnancy  and assessments of fertility
All pre-menopausal women who are not surgically  sterile will have pregnancy  testing at 
Screening . Additional pregnancy  testing might be performed if requested by local requirements.
Local pregnancy  testing and associated results will not be collected on the e CRF.
Highl y effective contraception is required for women of child- bearing potential during the study 
drug administration and for 3 months after the investigational medication is administered.
8.4.4 Ophthalmic examination
The ophthalmic exam ination (including IOP, Biomicroscop y, and Ophthalmoscopy ) will be 
performed at Screening and Baseline (pre-dose and post -dose) as noted below:
Intraocular pressure (IOP) – IOP will be measured in mmHg and entered in the eCRF.
Screening: IOP is assessed in both ey es(OU) at Screening.
Baseline: IOP is assessed in the study  eye (SE) ONLY; pre -dose and post -dose 
measurements are required at Baseline.
Post-dose I OP should be assessed, approximately  30 -60 minutes after the IVT 
injection and, if ≥ 25 mmHg, the assessment should be repeated until back to normal . 
Treatment and close mo nitoring of an elevated IOP should be performed by  the 
investiga tor according to clinical practice
Novartis Confidential Page 29
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
Biomicroscopy (slit lamp examination) –The slit lamp examination will be completed 
to examine the structures of the study  eye. The results of the examination must be 
recorded in the source documents.
Screening: Biomicroscopy  is assessed in both ey es(OU).
Baseline: Biomicroscop y is assessed in the study eye (SE) ONLY; pre -dose and , if 
required, post dose examination s.
Ophthalmoscopy (funduscopy) – Ophthalmoscopy  will be completed to examine the 
peripheral retina and confirm that an intravitreal injection can be safely performed. 
Theresults of the examination must be recorded in the source documents.
Screening: Ophthalmoscopy  is assessed in both ey es(OU) at Screening.
Baseline: Ophthalmoscopy  is assessed in the study  eye (SE) ONLY; pre -dose and, if 
required, post -dose examinations 
Note: Pupil dilation for the slit lamp examination and ophthalmoscopy  is optional according to 
local practice. 
Clinically  significant abnormal findings (as judged by  the masked investigator) from slit lamp 
or ophthalmoscopy  observations should be recorded as an AE in the eCRF.
8.4.5 Appropriateness of safety  measurements
Standard ECG intervals and morphology  variables wi ll be assessed, and QTcF and QTcB will 
be calculated. Cardiac assessments will be based on the QTcF, although QTcB will be used for 
comparative and historical control. ECG data is collected at several time points (Screening, 
Baseline and then continuously between Baseline 1h pre -injection through 48h , and on Day 3).
It is appropriate to explore the within -and between -patient exposure -effect relationship.
Laboratory  samples will be drawn at Screening in order to identify  a  potential electrol yte 
imbalance (e .g. hy pokalemia) that might affect ECG parameters and morphology .
The other safet y assessments selected are standard for this indication/ patient population.
8.5 Additional assessments
No additional tests will be performed on patient s entered into this study .
Novartis Confidential Page 30
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
9 Study  discontinuation and completion
9.1 Discontinuation
9.1.1 Discontinuation of study treatment
Since this is a single dose study , discontinuation of study  treatment is not applicable.
Patient s who decide they do not wish to participate in the study  further after the single dose
should NOT be considered withdrawn from the study  UNLESS they withdraw their consent 
(see Section 9.1.2 Withdrawal of informed consent). Where possible, they should return for 
the a ssessments indicated in the Assessment S chedule (Table 8-1). If they fail to return for 
these assessments for unknown reasons, every  effort ( e.g. telephone, e-mail, letter) should be 
made to contact the patient/pre -designated contact as specified in the lost to follow -up, 
seeSection 9.1.3 Lost to follow -up. This contact should preferabl y be done according to the 
study  visit schedule.
If the patient cannot or is unwilling to attend any  visit(s), the site staff should maintain regular 
telephone contact with the patient , or with a person pre-designated by the patient. This telephone 
contact should preferably be done according to the study  visit schedule.
9.1.1.1 Replacement policy
Patient s will not be replaced on study . However, if a patient is conside red as non-evaluable , 
enrollment of a new patient will be considered by Novartis if there areless than the required 
number of patient sthat complete t he study . 
9.1.2 Withdrawal of informed consent
Patient s may voluntaril y withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs onl y when a patient :
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the patient ’s decision to withdraw his/her consent and 
record this informati on.
Study  treatment must not be given (if not yet injected) and no further assessments conducted, 
and the data that would have been collected at subsequent visits will be considered missing.
Further attempts to contact the patient are not allowed unless safety findings require 
communicating or follow -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the patient ’s study  withdrawal should be made as detailed in the 
Assessment Schedule (Table 8 -1).
Novartis will continue to keep and use collected study information (including any data resulting from 
the analy sis of a patient ’s samples until the time of withdrawal) according to applicable law.
Novartis Confidential Page 31
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
All biological samples not yet analyzed at the time of withdrawal may  still be used for further 
testing/anal ysis in accordance with the terms of this protocol and of the informed consent form.
9.1.3 Lost to follow -up
For patient s whose status is unclear because they  fail to appear fo r study  visits without stating 
an intention to discontinue or withdraw, the investigator must show "due diligence" by 
documenting in the source documents steps taken to contact the patient , e.g. dates of telephone 
calls, registered letters, etc. A patient should not be considered as lost to follow -up until due 
diligence has been completed or until the end of the study .
9.1.4 Early  study termination by  the sponsor
The study  can be terminated by  Novartis at an y time .
Reasons for earl y termination:
Unexpected, significant, or unacceptable safety riskto patient s enrolled in the study
Decision based on recommendations from applicable board(s) after review of safet y and 
efficacy  data
Discontinuation of study  drug development
In taking the decision to terminate, Novartis will alway s consider patient welfare and safety. 
Should early  termination be necessary , patient s must be seen as soon as possible and treated as 
a prematurely withdrawn patient . The investigator may be informed of additional procedures t o 
be followed in order to ensure that adequate consideration is given to the protection of the 
patient ’s interests. The investigator or sponsor depending on local regulation will be responsible 
for informing IRBs/IECs of the early termination of the trial.
9.2 Stud y completion and post -study  treatment
Study  completion is defined as when the last patient finishes their End of Study  (EOS) visit and 
any repeat assessments associated with this visit have been documented and followed -up 
appropriatel y by the Investigator ,or, in the event of an early study  termination decision, the 
date of that decision .
All treated patient s will have a safet y follow -up call conducted on Day 31.The information 
collected during this call is kept as source documentation. All SAEs reported during this time 
period must be reported as described i n Section 10.1.3 SAE reporting and SOM. Documentation 
of attempts to contact the patient arerecorded in the source documentation .
Continuing care should be provided by the investigator and/or referring physician after the 
conclusion of the trial based on patient availability  for follow -up. 
This care may  include:
Enrollment in an extension study or managed access program , if any are available
Initiation of standard of care treatment (approved treatment for nAMD) or other treatment , 
under the responsibility of the investigator and/or referring ph ysician
Novartis Confidential Page 32
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign [including abnormal laboratory  findings], symptom or disease) in a patient or 
clinical investigation patient after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The investigator has the responsibility  for managing the safet y of the individ ual patient and 
identify ing adverse events.
Novartis qualified medical personnel will be readily  available to advise on trial related medical 
questions or problems.
The occurrence of adverse events must be sought by non -directive questioning of the patient at 
each visit during the study. Adverse events also may be detected when they are volunteered b y 
the patient during or between visits or through physical examination findings, laboratory  test 
findings, or other assessments.
Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, 
accompanied by the following information (as far as possible) (if the event is serious refer to
Section 10.1.2 Serious adverse events):
1.The severit y grade:
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
2. Its rela tionship to the study  treatment .If the event is due to lack of efficacy or progression 
of underl ying illness (i.e. progression of the study indication) the assessment of causality 
will usually  be ‘Not suspected.’ The rationale for this guidance is that the symptoms of a 
lack of efficacy or progression of underl ying illness are not caused by the trial drug, they 
happen in spite of its administration and/or both lack of efficacy  and progression of 
underly ing disease can only be evaluated meaningfull y by an analysis of cohorts, not on a 
single patient
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not recovered/not 
resolved must be reported
4. W hether it constitutes anSAE (see Section 10.1.2 Serious adverse events for definition of 
SAE) and which seriousness criteria have been met
5. A ction taken regarding with study  treatment
Novartis Confidential Page 33
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
All adverse events must be treated appropriately . Treatment may include one or more of the 
following:
Dose not changed
Dose reduced/incre ased
Drug interrupted/withdrawn
6. Its outcome
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history  of the patient.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for at least 30 days following the last dose of 
study  treatment.
Once an adverse event is detected, it must be followed unt il its resolution or until it is judged to 
be permanent (e.g. continuing at the end of the study ), and assessment must be made at each 
visit (or more frequently, if necessary) of an y changes in severity, the suspected relationship to 
the interventions requ ired to treat it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator ’sBrochure (IB).
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside ofnormal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typical in patient s with 
the underl ying disease.
Follow the instructions found in the Site Operations Manual for data capture methodology 
regarding AE collection for patient s that fail screening.
10.1.2 Serious adverse events
An SAE is defined as any adverse event appearance of (or worsening of any pre-existing)
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the following 
criteria:
Fatal
Life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (please refer to the ICH-E2D Guidelines 2004 ).
Novartis Confidential Page 34
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
Results in persist ent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for: 
Routine treatment or monitoring of the studied indication , not associated with 
any deterioration in condition 
Elective or pre -planned treatment for a pre -existing condition that is unrelated to 
the indication under study  and has not worsened since signing the information 
consent
Social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
Treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission
Is medicall y significant, e.g. defined as an event that jeopardizes the patient or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situati ons should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospitalization but might jeopardize the patient or might 
require intervention to prevent one of the other outcomes listed above. Such events should be 
considered as “medicall y significant”. Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospitalization or development of dependency  orabuse (please refer to the 
ICH-E2D Guidelines 2004 ).
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met and the malignant neoplasm is not a disease progression of the 
study  indication.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred. 
10.1.3 SAE reporting
To ensure patient safet y, every SAE, regardless of causalit y, occurring after the patient has 
provided informed consent and until 30 days following thelast administration of study  
treatment if there are post-treatment follow -up visits with no required procedures must be 
reported to Novartis safety  within 24 hours of learning of its occurrence. Detailed instructions 
regarding the submission process and r equirements are provided to each site.
Screen failures ( e.g.a patient who is screened but is not treated)
SAEs occurring after the patient has provided informed consent until the time the patient is 
deemed a Screen Failure must be reported to Novartis. 
Novartis Confidential Page 35
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
Treated Patients
SAEs collected between time patient signs ICF until 30 day s after the patient has disconti nued 
or stopped study  treatment must be reported to Novartis.
All follow -up information for the SAE including information on complications, progressi on of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up information. An SAE occurring at a 
different time interval or otherwise considered completely  unrelated to a previously  reported 
one must be reported separatel y as a new event.
If the SAE is not previously  documented in the Investiga tor’s Brochure (new occurrence) and 
is thought to be related to the study  treatment, a CMO & PS Department associate may urgentl y 
require further information from the investigator for health authorit y reporting. Novartis may 
need to issue an Investigator Notification (IN) to inform all investigators involved in an y stud y 
with the same study  treatment that this SAE has been reported.
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory requirements in participating countries.
Any SAEs experienced after the 30 day period following the last administration of study  
treatment should only be reported to Novartis Safety  if the investigator suspects a causal 
relationship to study  treatment.
10.1.4 Pregnancy  reporting
To ensure patient safet y, each pregnancy  occurring after signing the informed consent form 
must be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, congenital abnormalities, 
or maternal and/or newborn complications.
Pregnancy  should be recorded and reported by the investigator to the Novartis Chief Medical 
Office and Patient Safety  (CMO&PS). Pregnancy  follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the investigational 
treatment of any pregnancy  outcome. Any SAE experienced during pregnancy  must be reported.
10.1.5 Reporting of study treatment errors including misuse/abuse
Study  treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not it is associated with an AE/SAE and reported 
to Safety  (only if associated with an SAE ). 
Misuse or abuse will be collected and reported in the safet y database irrespective of it being 
associated with an AE/SAE within 24 hours of Investigator’s awareness.
Novartis Confidential Page 36
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error type Document in Dosing 
CRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated 
with an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.
10.2 Additional Safety  Monitoring
Not applicable
11 Data collection and database management
11.1 Data collection
Data not requiring a separate written record will be defined in the protocol and the Assessment 
Schedule ( Table 8 -1) and can be recorded directl y on the CRFs. All other data captured for this 
study  wi ll have an external originating source (either written or electronic) with the CRF not 
being considered as source .
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
Designated investigator staff will enter the data required by the protocol into the electronic Case 
Report Forms (eCRF). The eCRFs are built using fully  validated secure web -enabled software 
that conforms to 21 CFR Part 11 requirements. Automatic validation programs check for data 
discrepancies in the eCRFs, allow modification and/or verification of the entered data by the 
investigator staff. Investigator site staff will not be given access to the EDC system until they 
have bee n trained. 
The investigator/designee is responsi ble for assuring that the data recorded on CRFs (entered 
into eCRF) is complete, accurate, and that entry  and updates are performed in a timely  manner. 
The Investigator must c ertify  that the data entered is complete and accurate .
After thefinal database lock, the investigator will receive copies of the patient data for archiving 
at the investigational site.
All data should be recorded, handled and stored in a way that allows accurate reporting, 
interpretatio n, and verification.
Novartis Confidential Page 37
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
11.2 Database management and quality  control
Novartis personnel (or designated CRO) will review the data entered by investigational staff 
for completeness and accuracy . Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values. Queries aresent 
to the investigational site via the EDC s ystem. Designated investigator site staff are required to 
respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and ad verse events will be coded using the 
Medical Dictionary  for Regulatory  Activities (MedDRA) terminology .
Once all of the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and made availab le for data analy sis/moved to restricted 
area to be accessed bytheindependent programmer and statistician. Any changes to the 
database after that time can only be made after written agreement by Novartis development 
management.
11.3 Site monitoring
Before study initiation, ata site initiation visit or at an investigator’s meeting, a Novartis or 
delegated CRO representative will review the protocol and data capture requirements 
(i.e.eCRFs) with the investigators and their staff. During the study , Novartis employ s several 
methods of ensuring protocol and GCP compliance and the quality /integrity  of the sites’ data. 
The field monitor will visit the site to check the completeness of patient records, the accuracy  
of data capture / data entry , the adherence to the protocol and to Good Clinical Practice, the 
progress of enrollment, and to ensure that study treatment is being stored, dispensed, and 
accounted for according to specifications. Key study personnel must be available to assist the 
field monitor during these visits. Continuous remote monitoring of each site’s data may be 
performed by a  centralized Novartis or delegated CRO /CRA organization. Additionally , a 
central analytics organization may analyze data & identify  risks & trends for site operational 
parameters, and provide reports to Novartis clinical teams to assist with trial oversight.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
patient ’s file. The investigator must also keep the original informed consent form signed b y the 
patient (a signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criter ia, 
documentation of SAEs and of data that will be used for all primary  variables. Additional checks 
of the consistency  of the source data with the CRFs are performed according to the study -
specific monitoring plan. No information in source documents about the identity  of the patient s 
will be disclosed.
Novartis Confidential Page 38
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
12 Data analy sis and statistical methods
Any data analy sis carried out independently  by the investigato r should be submitted to Novartis 
before publication or presentation.
12.1 Analysis sets
The safet y analysis set will include all patient s that received one (1) IVT injection of 
brolucizumab 6 mg. All analy ses will be performed on the Safety  Set unless otherwis e specified.
12.2 Subject demographics and other baseline characteristics
Demographic and Baseline characteristics will be summarized descriptively .Categorical data 
will be presented as frequencies and percentages. For continuous data, mean, standard deviation , 
median, minimum and maximum will be presented .
Relevant medical histories and current medical conditions at Baseline will be summarized by 
system organ class and preferred term .Separate tables will be presented for ocular and 
non-ocular histories and co nditions.
For selected characteristics, listings will be presented by  patient.
12.3 Treatments
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study  treatment will be listed and summarized according to the Anatomical Therapeutic 
Chemical (ATC) classification sy stem.
12.4 Analysis of the primary  endpoint(s)
The primary  objective of this study  is to collect information on ECG after intravitreal injection 
of brolucizumab 6 mg in patients with nAMD . 
12.4.1 Definition of primary  endpoint(s) 
The primary  endpoints include the following:
Incidence between 20 and 24 h post- injection of clinically  relevant treatment emergent 
changes in HR, PR, QRS, and QTc (heart rate corrected QT using Fridericia’s formula, 
QTcF) interval (ms)
12.4.2 Statistical model, hypothesis, and method of analy sis
There are no formal h ypotheses in this study . 
Incidences between 20 and 24 h post-injection of clinically  relevant treatment emergent changes 
in HR, PR, QRS, and QTc interval will be listed by patient. 
The frequency  and proportion of patient s with change from baseline in QTcF ≥ 30 ms and 
≥ 60 ms between 20 and 24 h post-injection will be summarized. Listings of patient s with 
change from baseline in QTcF ≥ 30 ms and ≥ 60 ms between 20 and 24 h post -injection will be 
provided.
Novartis Confidential Page 39
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
The frequency  and proportion of patient s with QTcF > 450, 480, and 500 ms between 20 and 
24 h post -injection will be summarized. Listings of patient s with QTcF > 450, 480, and 500 ms 
between 20 and 24 h post -injection will be prov ided separately .
Holter ECG data between 20 and 24 h post-injection will be plotted by patient , and 
abnormalities will be flagged. 
Further details on anal yses of primary  endpoints will be provided in the SAP.
12.4.3 Handling of missing values/censoring/discontin uations
There will be no imputation of missing data .Only observed data will be used for theanaly ses.
12.4.4 Sensitivity and Supportive analy ses
There will be no sensitivity  analy ses.
12.5 Analysis of secondary  endpoints
The secondary  endpoints areocular and non-ocular AEs (including clinically  relevant ECG 
abnormalities) until the end of the study .
12.5.1 Safety  endpoints
A treatment -emergent adverse event is defined as any adverse event that develops after 
initiation of the study  treatment or any event already  present that worsens following exposure 
to the study  treatment, until the end of study . Only treatment-emergent adverse events will be 
presented in the summary tables.
Adverse events will be coded using the MedDRA dictionary  and presented by system organ 
class (SOC) and preferred term (PT). AEs will be presented based on the number and percentage 
of patient s with at least one AE in the category  of interest. Separate tables will be provided for 
ocular events in the study  eye and fellow eye and non-ocular events (including clinicall y 
relevant ECG abnormalities).
Patient listings of all adverse events will be provided. Deaths and other serious or clinicall y 
significant non -fatal adverse events will be listed separately .
12.6 Interim analy ses
Not applicable .
12.7 Sample size calculation
12.7.1 Primary  endpoint(s)
The PMDA of Japan requested a sample size of approximately  10 to 15 patient sfor this study . 
No sample size calculations were performed . 
Novartis Confidential Page 40
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21) , and with the ethical 
principles laid down in the Declaration of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from 
the Institutional Review Board/ Independent Ethics Committee (IRB/IEC) for the trial protocol, 
written informed consent form, consent form updates, patient recruitment procedures 
(e.g., advertisements) and any other written information to be provided to patient s. Prior to 
study  start, the investigator is required to sign a protocol signature page confirming his/her 
agreement to conduct the study  in acco rdance with these documents, all of the instructions and 
procedures found in this protocol ,and to give access to all relevant data and re cords to Novartis 
monitors, auditors, Novartis Quality Assurance representatives, designated agents of Novartis, 
IRBs/IECs, and regulatory  authorities as required. If an inspection of the clinical site is 
requested by a regulatory authority , the investigat or must inform Novartis immediately  that this 
request has been made.
13.3 Publication of study  protocol and results
The protocol will be registered in a publicly  accessible database such as clinicaltrials.gov and 
as required in EudraCT. In addition, after study completion (defined as last patient last visit) 
and finalization of the study  report ,the results of this trial will be and posted in a publicly  
accessible database of clinical trial results, such as the Novartis clinical trial results website and 
all required Health Authority  websites (e.g. Clinicaltrials.gov, EudraCT, etc.).
For details on the Novartis publication policy  including authorship criteria, please refer to the 
Novartis publication policy  training materials that were provided at the trial investigator 
training.
13.4 Qualit y Control and Quality  Assurance
Novartis maintains a robust Quality Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and Novartis systems are performed by auditors, 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.
Audi ts are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written Novartis processes
Novartis Confidential Page 41
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
14 Protocol adherence
This protocol defines the study objectives, the study procedu res,and the data to be collected on 
study  participants. Additional assessments required to ensure safety  of patient s should be 
administered as deemed necessary  on a case by case basis. Under no circumstances including 
incidental collection is an investiga tor allowed to collect additional data or conduct any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despite this interdiction prohibition, data, information, 
observation would be incidentally  collected, the investigator shall immediately  disclose it to 
Novartis and not use it for any purpose other than the study , except for the appropriate 
monitoring on study  participants.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IR B/IEC and health authorities, where required, it cannot be implemented.
14.1 Protocol amendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are required for patient safet y may be implemented immediately 
provided the health authorities are subsequently  notified by protocol amendment and the 
reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safet y of any patient included in this 
study , even if this action represents a deviation from the protocol. In such cases, Novartis should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.
Novartis Confidential Page 42
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
15 References
References are available upon request
Blinder KJ, Bradley  S, Bressler NM, et al (2003 ) Effect of lesion size, visual acuit y, and 
lesion composition on visual acuity  change with and without verteporfin therapy  for choroidal 
neovascularization secondary  to age -related macular degeneration: TAP and VI P report no. 1. 
Am J Ophthalmol . 136:407 –18.
Bloch SB, Larsen M, Munch I C(2012) Incidence o f legal blindness from age -related macular 
degeneration in Denmark: Year 2000 to 2010. Am J Ophthalmol. 153:209 -13.
Campbell JP, Bressler SB, Bressler NM (2012) Impact of availabilit y of anti -vascular 
endothelial growth factor therap y on visual impairment and blindness due to neovascular age -
related macular degeneration. Arch Ophthalmol. 130:794-5.
Ferris FL, Fine SL, Hy man L (1984) Age-related macular degeneration and blindness due to 
neovascular maculopathy. Arch Ophthalmol. 102:1640 -42.
ICH E2D (2004) Clinical Safety  Data Management: Definitions and Standards for expedited 
reporting. Accessed from: 
http://www.ema.europa.eu/docs/en_GB/document_library /Scientific_guideline/2009/09/WC5
00002807.pdf Accessed on: 02Dec2016.
Kawasaki R, Yasuda M, Song S, et al(2010) The prevalence of age- related macular degeneration in 
Asians : A sy stematic review and meta -analysis. Ophthalmology. 117:921 -27.
Malik M, Garnett CE, Zhang J (2010) Thorough QT Studies: Questions and Quandaries. Drug 
Saf. 33(1):1-14.
Lim L S, Mitchell P, Seddon JM, et al (2012) Age -related macular degeneration. L ancet. 
379:1728-38.
Miller JW (2013) Age-Related Macular Degeneration Revisited – Piecing the Puzzle: The 
LXIX Edward Jackson Memorial Lecture. Am J Ophthalmol. 155:1-35.
Rein D B, Wittenborn BS, Zhang X, et al (2009) Vision Health Cost -Effectiveness Study  
Group. Forecasting age -related macular degeneration through the year 2050. Arch 
Ophthalmol. 127:533 -40.
Shah AR, Del Priore L V(2007) Progressive visual loss in subfoveal exudat ion in age-related 
macular degeneration: a meta -analysis using Lineweaver -Burke plots. Am J Ophthalmol. 
143:83 -89.
Shah AR, Del Priore LV (2009) Natural history  of predominantly  classic, minimally  classic 
and occult subgroups in age -related macular degener ation. Am J Ophthalmol. 116:1901 -07.
Smith W, Assink J, Klein R, et al (2001) Risk factors for age -related macular degeneration: 
Pooled findings from three continents. Ophthalmology. 108:697-704.
Spilsbury  K, Garrett KL, Shen WY, et al (2000) Over expression of vascular endothelial 
growth factor (VEGF) in the retinal pigment epithelial leads to the development of choroidal 
neovascularization. Am J Pathol. 157:135-44.
Novartis Confidential Page 43
Clinical Trial Protocol (Version No. 00) Protocol No. CRTH258A2309
Wong WL , Su X, Li X, et al (2014) Global prevalence of age- related macular degeneration 
anddisease burden projection for 2020 and 2040: a sy stematic review and meta -analysis. 
Lancet Glob Health;2:e106 -16.